Second Primary Cancers After Gastric Cancer, and Gastric Cancer as Second Primary Cancer.
cancer etiology
cancer incidence
relative risk
second primary cancer
stomach cancer
Journal
Clinical epidemiology
ISSN: 1179-1349
Titre abrégé: Clin Epidemiol
Pays: New Zealand
ID NLM: 101531700
Informations de publication
Date de publication:
2021
2021
Historique:
received:
28
01
2021
accepted:
01
03
2021
entrez:
9
7
2021
pubmed:
10
7
2021
medline:
10
7
2021
Statut:
epublish
Résumé
Second primary cancers (SPCs) are increasing, which may negatively influence patient survival. Gastric cancer (GC) has poor survival and when it is diagnosed as SPC it is often the cause of death. We wanted to analyze the risk of SPCs after GC and the risk of GC as SPC after any cancer. Such bidirectional analysis is important in relation to fatal cancers because SPCs may be under-reported in the short-term survival period. Cancers were obtained from the Swedish Cancer Registry from years 1990 through 2015. Standardized incidence ratios (SIRs) were used to estimate bidirectional relative. We identified 23,137 GC patients who developed 1042 SPCs (4.5%); 2158 patients had GC as SPC. While the risk for three SPCs was increased after GC, seven first primary cancers were followed by an increased risk of GC as SPC, including esophageal, colorectal, bladder, squamous cell skin and breast cancers and non-Hodgkin lymphoma. Breast cancer, which was followed by a diagnosis of second GC, showed an excess of lobular histology. Multiple primary cancers in the same individuals may signal genetic predisposition. Accordingly, the association of GC with breast cancer may be related to mutations in the
Sections du résumé
BACKGROUND
BACKGROUND
Second primary cancers (SPCs) are increasing, which may negatively influence patient survival. Gastric cancer (GC) has poor survival and when it is diagnosed as SPC it is often the cause of death. We wanted to analyze the risk of SPCs after GC and the risk of GC as SPC after any cancer. Such bidirectional analysis is important in relation to fatal cancers because SPCs may be under-reported in the short-term survival period.
METHODS
METHODS
Cancers were obtained from the Swedish Cancer Registry from years 1990 through 2015. Standardized incidence ratios (SIRs) were used to estimate bidirectional relative.
RESULTS
RESULTS
We identified 23,137 GC patients who developed 1042 SPCs (4.5%); 2158 patients had GC as SPC. While the risk for three SPCs was increased after GC, seven first primary cancers were followed by an increased risk of GC as SPC, including esophageal, colorectal, bladder, squamous cell skin and breast cancers and non-Hodgkin lymphoma. Breast cancer, which was followed by a diagnosis of second GC, showed an excess of lobular histology.
CONCLUSION
CONCLUSIONS
Multiple primary cancers in the same individuals may signal genetic predisposition. Accordingly, the association of GC with breast cancer may be related to mutations in the
Identifiants
pubmed: 34239328
doi: 10.2147/CLEP.S304332
pii: 304332
pmc: PMC8260108
doi:
Types de publication
Journal Article
Langues
eng
Pagination
515-525Informations de copyright
© 2021 Zheng et al.
Déclaration de conflit d'intérêts
A.H. is a shareholder in Targovax ASA. A.H. reports personal fees and is an employee and shareholder in TILT Biotherapeutics Ltd. The other authors declared no conflicts of interest.
Références
Cancer Lett. 2015 Dec 1;369(1):152-66
pubmed: 26319898
Cancers (Basel). 2020 Dec 11;12(12):
pubmed: 33322525
Clin Epidemiol. 2018 Oct 11;10:1457-1466
pubmed: 30349393
Acta Oncol. 2010 Jun;49(5):725-36
pubmed: 20491528
Aliment Pharmacol Ther. 2019 Sep;50(6):654-663
pubmed: 31347731
Gut. 2006 Jun;55(6):896-8
pubmed: 16698758
Cancer. 2003 Jun 15;97(12 Suppl):3133-275
pubmed: 12784323
Gac Sanit. 2020 Jul - Aug;34(4):393-398
pubmed: 30527910
Transl Gastroenterol Hepatol. 2020 Oct 05;5:52
pubmed: 33073047
Int J Cancer. 2017 Mar 1;140(5):1091-1101
pubmed: 27870055
CA Cancer J Clin. 2014 Jan-Feb;64(1):9-29
pubmed: 24399786
Int J Cancer. 2018 Nov 15;143(10):2449-2457
pubmed: 30238973
Lancet Gastroenterol Hepatol. 2020 Jan;5(1):42-54
pubmed: 31648970
J Invest Dermatol. 2020 Jan;140(1):48-55.e1
pubmed: 31288011
Br Med Bull. 2014 Jun;110(1):5-22
pubmed: 24816203
J Family Med Prim Care. 2020 Jun 30;9(6):2659-2663
pubmed: 32984103
Cancer Manag Res. 2019 Dec 13;11:10477-10486
pubmed: 31853199
Ann Transl Med. 2020 Nov;8(22):1484
pubmed: 33313229
Surg Clin North Am. 2015 Oct;95(5):1053-66
pubmed: 26315523
Cancer Epidemiol. 2017 Oct;50(Pt A):85-91
pubmed: 28843176
Int J Cancer. 2020 Feb 15;146(4):970-976
pubmed: 31054153
Nat Rev Clin Oncol. 2013 May;10(5):289-301
pubmed: 23529000
Cancer Med. 2013 Oct;2(5):718-24
pubmed: 24403237
United European Gastroenterol J. 2017 Jun;5(4):473-478
pubmed: 28588876
Nat Rev Nephrol. 2010 Sep;6(9):511-9
pubmed: 20736984
JAMA Oncol. 2017 Dec 1;3(12):1702-1706
pubmed: 28772289
Oncotarget. 2016 Aug 9;7(32):52307-52316
pubmed: 27447571
Curr Gastroenterol Rep. 2017 Aug;19(8):36
pubmed: 28730504
Acta Oncol. 2018 Apr;57(4):440-455
pubmed: 29226751
Transl Gastroenterol Hepatol. 2019 Jul 29;4:55
pubmed: 31463414
Cancer Med. 2019 Jan;8(1):400-407
pubmed: 30479046
Cancer Control. 2009 Jan;16(1):14-22
pubmed: 19078925
Lancet. 2020 Aug 29;396(10251):635-648
pubmed: 32861308
Clin Epidemiol. 2018 Sep 04;10:1169-1179
pubmed: 30233251
Gut. 2018 Jul;67(7):1306-1316
pubmed: 28754778
Gastric Cancer. 2016 Apr;19(2):490-497
pubmed: 25772342
Am J Clin Pathol. 1975 Apr;63(4):453-74
pubmed: 1091134
Acta Oncol. 1997;36(5):465-9
pubmed: 9292741
Lancet Oncol. 2020 Aug;21(8):e386-e397
pubmed: 32758476
Int J Cancer. 1995 Jan 17;60(2):183-9
pubmed: 7829213